Demyelinating diseases research hub

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

This clinical trial is testing a new medicine called efgartigimod for adults having a severe flare-up of a nerve condition, such as multiple sclerosis. Researchers want to see if adding this drug to standard steroid drips helps patients recover their eyesight, strength, and mobility faster and more completely.